SINOVAC Appoints New Board Following Privy Council Ruling
SINOVAC Announces New Board Following Privy Council Judgment and Outlines Next Steps Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading biopharmaceutical company in China, has announced significant developments…
Identiv and Novanta Form Strategic Partnership to Accelerate RFID Adoption in Healthcare OEMs
Identiv and Novanta Forge Strategic Partnership to Accelerate Adoption of RFID Solutions in Healthcare OEMs Novanta Inc., a leading global technology supplier serving the medical device and life sciences markets,…
Immune-Onc Doses First Patient in IO-108 Phase 1b/2 Liver Cancer Trial with Roche
Immune-Onc Therapeutics Doses First Patient with IO-108 in Global Phase 1b/2 Liver Cancer Study in Collaboration with Roche Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage biopharmaceutical company focused on developing…
IPA and RIBOPRO Partner to Advance mRNA-Based Antibody Discovery and Expand Immunotherapy Frontiers
IPA and RIBOPRO Forge Strategic Partnership to Revolutionize mRNA-Based Antibody Discovery and Expand Immunotherapy Horizons ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody…
Aurinia Pharmaceuticals Announces Q4 & 2024 Financial Results, Updates on Corporate Progress
Aurinia Pharmaceuticals Announces Strong Financial Performance for Q4 and Full Year 2024, Provides Corporate Updates Fourth Quarter and Full-Year 2024 Financial Performance Highlights Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a leading…
Genethon Showcases Innovations in Gene Therapy on Rare Disease Day
Genethon Advances Gene Therapy Innovations on Rare Disease Day 2025 Genethon, a pioneering gene therapy research organization founded by the AFM-Telethon, marks Rare Disease Day by showcasing groundbreaking technological advancements…
Avitia Unveils AI-Powered Platform for Fast, Point-of-Care Cancer Testing
Avitia Unveils AI-Powered Platform for Fast, Point-of-Care Cancer Testing Avitia, an AI company providing end-to-end testing solutions to rapidly identify cancer mutations and applicable treatments, has officially launched its business…
LEO Pharma’s Anzupgo® Meets Phase 3 Endpoint in China for Chronic Hand Eczema
LEO Pharma’s Anzupgo® Meets Phase 3 Endpoint in China for Chronic Hand Eczema LEO Pharma A/S, a global leader in medical dermatology, has announced positive results from the double-blind treatment…
Healx Begins Phase 2 Trial Dosing for HLX-1502 in Neurofibromatosis Type 1
Healx Begins Phase 2 Trial Dosing for HLX-1502 in Neurofibromatosis Type 1 Healx, an AI-driven, clinical-stage biotechnology company focused on developing treatments for rare diseases, has announced a major milestone…
Glaukos Receives FDA Acceptance for Epioxa™ NDA Submission
Glaukos Receives FDA Acceptance for Epioxa™ NDA Submission Glaukos Corporation (NYSE: GKOS), a leading ophthalmic pharmaceutical and medical technology company specializing in innovative therapies for the treatment of glaucoma, corneal…
Bruker Expands Proteomics Capabilities with New Software at US HUPO
Bruker Expands Proteomics Capabilities with New Software at US HUPO At the 21st Annual US HUPO Conference, Bruker Corporation (Nasdaq: BRKR) announced significant advancements in 4D-Proteomics™ performance, software, and applications…
Halda Therapeutics Doses First Patient in HLD-0915 Phase 1/2 Trial for mCRPC
Halda Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of HLD-0915 for Metastatic Castration-Resistant Prostate Cancer Halda Therapeutics, a clinical-stage biotechnology company focused on developing a novel class of…